Most people taking Wegovy lose between 13% and 15% of their starting body weight over about a year and a half. For someone who weighs 250 pounds, that translates to roughly 33 to 38 pounds. Individual results vary widely, though, and several factors influence where you’ll land in that range.
What Clinical Trials Show
The landmark trial that led to Wegovy’s approval tested the 2.4 mg maintenance dose against a placebo over 68 weeks (about 16 months). Participants on Wegovy lost an average of around 15% of their body weight, while those on placebo lost roughly 2 to 3%. A newer trial testing a higher 7.2 mg dose over 72 weeks found even greater losses: 18.7% of body weight on average, compared to 15.6% with the standard 2.4 mg dose and 3.9% with placebo.
These percentages may sound modest, but they represent meaningful change. A person starting at 220 pounds could expect to lose around 30 to 40 pounds on the standard dose. At 300 pounds, losses in the range of 40 to 50 pounds are realistic. All trial participants also followed a reduced-calorie diet and increased their physical activity, so the drug works alongside lifestyle changes rather than replacing them.
What Happens in the First Few Months
You won’t start at the full dose. Wegovy follows a gradual titration schedule designed to reduce side effects, especially nausea. You begin with a very low weekly injection and step up every four weeks:
- Weeks 1 through 4: 0.25 mg
- Weeks 5 through 8: 0.5 mg
- Weeks 9 through 12: 1 mg
- Weeks 13 through 16: 1.7 mg
- Week 17 onward: 2.4 mg (maintenance dose)
During the first three to four months, weight loss is typically slower because you’re on lower doses. Many people notice appetite changes early on, but the most significant drops on the scale tend to happen after reaching the maintenance dose. Weight loss generally continues for 12 to 18 months before plateauing, so patience during the ramp-up period is important.
How Wegovy Causes Weight Loss
Wegovy is a synthetic version of a hormone your body already makes called GLP-1. When you eat, your gut releases GLP-1 to signal fullness. Wegovy mimics that signal but lasts much longer than the natural version, which breaks down in minutes.
The drug works through several pathways at once. It acts on appetite centers in the brain to reduce hunger and increase feelings of satisfaction after smaller meals. It also slows the rate at which food leaves your stomach, so you feel full longer after eating. On top of that, it promotes the release of other satiety-related hormones like leptin. The combined effect is that most people simply want to eat less, find it easier to stop eating when they’re satisfied, and spend less time thinking about food between meals.
How Wegovy Compares to Zepbound
Zepbound (tirzepatide) is the other major injectable weight loss medication, and head-to-head data now exists. In a direct comparison trial, people taking Zepbound lost about 50 pounds (20.2% of body weight) while those on Wegovy lost about 33 pounds (13.7%). Nearly a third of Zepbound users hit a 25% body weight reduction, compared to 16% of Wegovy users.
That’s a meaningful difference, but it doesn’t make Wegovy ineffective. Zepbound targets two gut hormones (GLP-1 and GIP) rather than one, which likely explains the edge. Some people respond better to one medication than the other, and factors like insurance coverage, side effect tolerance, and availability often play a role in which one you end up taking.
Keeping the Weight Off Long Term
A two-year trial (STEP 5) tracked whether weight loss holds up beyond the initial treatment period. While detailed published numbers from that study are limited, the broader pattern from semaglutide research is clear: people who stay on the medication tend to maintain their weight loss. People who stop typically regain a significant portion of the weight within a year. This is consistent with how obesity works as a chronic condition. The drug doesn’t reset your body’s weight set point permanently; it changes the hormonal signals that drive hunger and fat storage for as long as you take it.
This means most people should think of Wegovy as a long-term treatment rather than a short course. Discussing a realistic timeline with your prescriber is worthwhile, especially since stopping and restarting may require going through the titration schedule again.
Benefits Beyond the Scale
Weight loss on Wegovy also translates into measurable health improvements. The FDA approved Wegovy specifically to reduce the risk of heart attack, stroke, and cardiovascular death in adults with obesity or overweight who already have heart disease. In the trial that supported this approval, serious cardiovascular events occurred in 6.5% of people taking Wegovy compared to 8% on placebo. That 20% relative reduction is notable because it was independent of whether participants had diabetes, making Wegovy the first obesity medication approved for direct cardiovascular protection.
People also commonly see improvements in blood sugar levels, blood pressure, cholesterol, joint pain, sleep apnea, and overall mobility. For many, these changes matter more than the number on the scale.
Side Effects That Affect Results
The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These tend to be worst during dose increases and often improve over time. The gradual titration schedule exists specifically to ease this transition, and if a particular dose is hard to tolerate, your prescriber can delay the next increase by four weeks.
Some people find nausea severe enough that they eat very little during the early weeks. While this contributes to initial weight loss, it’s not a sustainable pattern and can lead to muscle loss if protein intake drops too low. Prioritizing protein-rich foods, eating smaller meals, and staying hydrated can help manage symptoms while keeping nutrition adequate. A small percentage of people discontinue treatment because of persistent GI issues, though most find the side effects manageable once they reach a stable dose.
Who Qualifies for a Prescription
Wegovy is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. It’s also approved for adolescents aged 12 and older whose BMI falls at or above the 95th percentile for their age and sex. Your prescriber will evaluate whether your overall health profile makes you a good candidate, taking into account other medications and any history of certain thyroid or pancreatic conditions.